All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

Philips is rolling out what it describes as a next-generation point-of-care ultrasound system, designed specifically for ...

A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. | The FDA is introducing a ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

KalVista Pharmaceuticals has become the latest biotech to face delays to the FDA’s decision-making, as the agency apparently ...